<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218722</url>
  </required_header>
  <id_info>
    <org_study_id>38RC16.046</org_study_id>
    <nct_id>NCT03218722</nct_id>
  </id_info>
  <brief_title>Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma</brief_title>
  <acronym>PROCOAG</acronym>
  <official_title>Impact of Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute traumatic coagulopathy (ATC) is common in severe trauma patients (around 25 to 30% of
      patients with severe trauma) and is associated with increased mortality. ATC is associated
      with fibrinogen and clotting factors deficiencies. Therefore, ATC management relies on early
      administration of fibrinogen and blood products in case of massive transfusion with a 1:1 or
      1:2 ratio between Fresh Frozen Plasma (FFP) and Red Blood Cells (RBC). This strategy relies
      on fast supply of FFP.

      To overcome delay for FFP ordering, transport and defrosting, the PROCOAG study proposes to
      use prothrombrin concentrate complex (PCC) as alternative to treat coagulation factor
      deficiency. PCC is readily available upon hospital arrival. In addition to fibrinogen
      treatment, it is thought that PCC can be efficient in ATC management, while reducing risks
      associated with massive transfusion.

      ProCoag is a randomized, controlled, double-blinded, parallel clinical trial aiming at
      showing superiority of early PPC+ fibrinogen strategy on fibrinogen only strategy for the
      management of patients at risk of massive transfusion.

      Early administration of PPC should optimize patient blood management and therefore reduce
      blood products transfused within the first 24 hours following a severe trauma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Labile blood products transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBC (Red Blood Cells) transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFP transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>This outcome is measured in number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Prothrombin ratio &lt; 1.5</measure>
    <time_frame>Within the first 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>Within the first 24 hours following admission</time_frame>
    <description>Hemostasis is defined as bleeding control in the surgical field or resolution of contrast blush after embolization during interventional radiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombo-embolic events</measure>
    <time_frame>ICU stay (an average of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 hours and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>Hospital stay (an average of 28 days)</time_frame>
    <description>Number of in-hospital days outside Intensive Care Unit (ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-Free Days</measure>
    <time_frame>ICU stay (an average of 21 days)</time_frame>
    <description>Number of days without mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days</measure>
    <time_frame>Within the first 28 days</time_frame>
    <description>Number of days outside hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOSE)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation status</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the strategy</measure>
    <time_frame>Day 8 and Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Shock, Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>PCC treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional strategy for ATC management without PCC (NaCl 0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pro-Thrombin Concentrate Complex</intervention_name>
    <description>Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.</description>
    <arm_group_label>PCC treatment</arm_group_label>
    <other_name>KANOKAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary admission for a severe trauma

          -  Out-of-hospital transfusion or RBC transfusion within the first hour following
             hospital admission

          -  Clinical prediction of massive transfusion or ABC score (Assessment of Blood
             Consumption) ≥ 2

          -  Informed consent signed by a relative or emergency procedure

          -  Affiliation to a social security system

        Exclusion Criteria:

          -  Cardiac arrest before randomisation

          -  Secondary transfer from another hospital (a technical stop is accepted)

          -  Post-traumatic lesions out of therapeutic resources with death expected in the hour
             following hospital admission

          -  Anti-coagulation treatment (K anti-vitamine, new oral anticoagulant)

          -  Pregnancy

          -  Hypersensitivity to active substances or one of the excipients of KANOKAD®

          -  Patient treated with an experimental medicine within the last 30 days

          -  Decision of therapeutic limitation before randomisation

          -  Patient protected by article L1121-6 and L1121-7 of the French Public health code and
             patient subject to a legal protection order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BOUZAT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre BOUZAT, PU-PH</last_name>
    <phone>04 76 76 52 95</phone>
    <email>pbouzat@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anais ADOLLE</last_name>
    <phone>04 76 76 68 13</phone>
    <email>aadolle@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Annecy University Hospital</name>
      <address>
        <city>Annecy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrice Levrat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paër-sélim Abback, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bouzat, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Duranteau, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Garrigue, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Marcotte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - Marseille Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Léone, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Charbit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44 093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Asehnoune, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nîmes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Bobbia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Delhaye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Stéphane David, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute traumatic coagulopathy</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Severe hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

